abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Schizophrenia · Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis · MPLT
MapLight Therapeutics
MapLight Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
atlanta, USA HQ
2017 Founded
7 Employees
Public company Type
MPLT · NYSE Ticker
Company details
- Status
- Public
- HQ
- atlanta, USA
- Founded
- 2017
- Employees
- 7
- Programs
- 5
- Drugs
- 5
- Patents
- 0
MapLight Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MapLight Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to MapLight Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to MapLight Therapeutics in public FDA and regional records.
-
Development asset linked to MapLight Therapeutics in public FDA and regional records.